Repligen (RGEN)
NASDAQ:RGEN
Want to see RGEN full AI Analyst Report?
RGEN Stock Chart & Stats
$131.21
$0.11(0.07%)
At close: 4:00 PM EST
$131.21
$0.11(0.07%)
Day’s Range― - ―
52-Week Range$100.99 - $175.77
Previous CloseN/A
Volume111.19K
Average Volume (3M)1.17M
Market Cap
$7.45B
Enterprise Value$7.64B
Total Cash (Recent Filing)$784.53M
Total Debt (Recent Filing)$687.62M
Price to Earnings (P/E)144.8
Beta1.05
Next Earnings
Aug 04, 2026EPS Estimate
0.45Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.91
Shares Outstanding56,407,740
10 Day Avg. Volume994,049
30 Day Avg. Volume1,171,490
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)4.38
Price to Sales (P/S)12.48
P/FCF Ratio98.13
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue10.01
Enterprise Value/Gross Profit19.91
Enterprise Value/Ebitda44.27
Forecast
1Y Price Target
$165.17Price Target Upside25.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)2
Revenue Forecast (FY)$822.75M
Bulls Say, Bears Say
Bulls Say
Strong Cash Generation And FCF ConversionConsistent positive operating and free cash flow, with FCF near ~80% of net income, indicates durable cash conversion. This supports reinvestment in R&D, modest capex (~3–4% of revenue), funding of transformation initiatives, and reduces reliance on external financing over the medium term.
Manageable Leverage And Solid Capital BaseDebt roughly one-third of equity and a growing equity base provide balance‑sheet flexibility to fund organic growth, strategic partnerships, or bolt‑on M&A without excessive leverage stress. That structure also cushions the company through cyclical ups/downs in bioprocessing demand.
High-growth Franchise Mix And Margin ExpansionMultiple franchises showing strong, differentiated growth (Analytics, Chromatography, Proteins) alongside reported gross‑ and operating‑margin expansion points to sustainable revenue mix improvement. Durable demand across consumables, systems and analytics supports repeatable revenues and structural margin upside.
Bears Say
Uneven Multi-year Growth And Muted ReturnsThe company’s revenue and margin path has been bumpy, with a notable drop in 2023 and only a partial recovery thereafter. Low single‑digit ROE and uneven multi‑year performance suggest execution and demand cyclicality risks that could constrain sustained return generation over the medium term.
Customer Capex Timing Makes Revenue LumpyA material portion of higher‑ticket systems and capital equipment sales depends on customer facility readiness and discretionary capex cycles. That makes revenue recognition and margin delivery timing uncertain, increasing short‑to‑medium‑term volatility and complicating predictability of cash flows.
Intense Competition In China Requires LocalizationHeightened local competition in China creates sustainable pricing and share challenges unless the company fully localizes. The OEM partnership delays meaningful local revenue accretion until partner ramp in 2027, leaving a near‑term structural headwind in a high‑growth region.
Repligen News
RGEN FAQ
What was Repligen’s price range in the past 12 months?
Repligen lowest stock price was $100.99 and its highest was $175.77 in the past 12 months.
What is Repligen’s market cap?
Repligen’s market cap is $7.45B.
When is Repligen’s upcoming earnings report date?
Repligen’s upcoming earnings report date is Aug 04, 2026 which is in 44 days.
How were Repligen’s earnings last quarter?
Repligen released its earnings results on May 05, 2026. The company reported $0.48 earnings per share for the quarter, beating the consensus estimate of $0.384 by $0.096.
Is Repligen overvalued?
According to Wall Street analysts Repligen’s price is currently Undervalued.
Does Repligen pay dividends?
Repligen does not currently pay dividends.
What is Repligen’s EPS estimate?
Repligen’s EPS estimate is 0.45.
How many shares outstanding does Repligen have?
Repligen has 56,407,740 shares outstanding.
What happened to Repligen’s price movement after its last earnings report?
Repligen reported an EPS of $0.48 in its last earnings report, beating expectations of $0.384. Following the earnings report the stock price went up 6.26%.
Which hedge fund is a major shareholder of Repligen?
Currently, no hedge funds are holding shares in RGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Repligen Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$165.17 (25.88% Upside)
$165.17 (25.88% Upside)
Blogger Sentiment
Neutral
RGEN Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.7%
Last 30 Days ▲ 7.6%
Last 30 Days ▲ 7.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
12.31%
12-Months-Change
Fundamentals
Return on Equity
2.46%
Trailing 12-Months
Asset Growth
2.76%
Trailing 12-Months
Company Description
Repligen
Repligen Corporation specializes in the creation and distribution of advanced bioprocessing technologies and integrated systems. These solutions are vital for various stages of biological drug production, serving clients across North America, Europe, the Asia Pacific region, and other international markets. The company's diverse product portfolio includes crucial components for biomanufacturing. This encompasses Protein A ligands, which serve as the key binding elements within Protein A affinity chromatography resins, as well as specialized cell culture growth factors. In the realm of chromatography, Repligen offers a range of products: Its OPUS line features pre-packed chromatography columns, instrumental in purifying biologics, alongside smaller-scale OPUS columns designed for high-throughput process development screening, viral clearance validation studies, and the scaling-down of chromatography processes. Additionally, the company supplies ELISA test kits and chromatography resins marketed under the CaptivA brand. Repligen also boasts an extensive suite of filtration products. This includes XCell Alternating Tangential Flow systems, which are filtration devices utilized in upstream perfusion and cell culture processing. For downstream applications like biologic drug concentration and formulation, they provide TangenX flat sheet cassettes. Other filtration offerings encompass KrosFlo tangential flow filtration and tangential flow depth filtration systems, Spectra/Por laboratory and process dialysis products, SpectraFlo dynamic dialysis systems, and ProConnex single-use hollow fibers. Furthermore, Repligen addresses process analytics with its slope spectroscopy systems, branded as SoloVPE, FlowVPE, and FlowVPX. Their clientele is broad, consisting of life sciences organizations, biopharmaceutical and diagnostics companies, laboratory researchers, and contract manufacturing organizations. Repligen also collaborates with partners, such as Navigo Proteins GmbH, on the development of various affinity ligands. The corporation was founded in 1981 and maintains its corporate headquarters in Waltham, Massachusetts.
RGEN Company Deck
RGEN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call was predominantly positive: the company reported healthy top-line growth ($194M, +15% reported, +11% organic), notable margin expansion (gross margin +180 bps, operating margin +160 bps), strong franchise performances (Analytics +50%+, Chromatography >25%, Proteins mid-teens), solid cash position ($785M), and raised adjusted EPS guidance. Management launched a transformation office targeting at least 1 point of annualized margin benefit by end of 2027 and announced a strategic OEM partnership in China. Key headwinds are mostly timing and structural: divestiture of a loss-making Polymem reduced revenue (~$7M), ATF/gene therapy customer timing moderated near-term growth (expected to rebound in 2027), some Q1 margin benefits may normalize, and there is execution risk around customer readiness for capital equipment and competition in China. Overall, positives (growth, margins, guidance, strategic initiatives, cash) materially outweigh the manageable lowlights tied to timing, one-off costs, and a small divestiture impact.View all RGEN earnings summariesRGEN Revenue Breakdown
44.00% North America
37.00% Europe
19.00% APAC/Other
RGEN Stock 12 Month Forecast
Average Price Target
$165.17
▲(25.88% Upside)
Technical Analysis
AptarGroup
―
Merit Medical Systems
―
Teleflex
―
Stevanato Group
―
Bausch + Lomb Corporation
―
Ownership Overview
0.68% Insiders
42.77% Mutual Funds
33.93% Other Institutional Investors
0.36% Public Companies and
Individual Investors